Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) EBT (2016 - 2025)

Historic EBT for BioCorRx (BICX) over the last 17 years, with Q3 2025 value amounting to -$808502.0.

  • BioCorRx's EBT rose 4656.33% to -$808502.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.3 million, marking a year-over-year increase of 1389.53%. This contributed to the annual value of -$5.2 million for FY2024, which is 3823.41% down from last year.
  • As of Q3 2025, BioCorRx's EBT stood at -$808502.0, which was up 4656.33% from -$1.4 million recorded in Q2 2025.
  • BioCorRx's EBT's 5-year high stood at -$808502.0 during Q3 2025, with a 5-year trough of -$1.6 million in Q1 2021.
  • For the 5-year period, BioCorRx's EBT averaged around -$1.1 million, with its median value being -$1.2 million (2022).
  • Per our database at Business Quant, BioCorRx's EBT crashed by 7444.09% in 2024 and then surged by 4656.33% in 2025.
  • Over the past 5 years, BioCorRx's EBT (Quarter) stood at -$1.3 million in 2021, then rose by 8.36% to -$1.2 million in 2022, then increased by 16.68% to -$969009.0 in 2023, then decreased by 26.69% to -$1.2 million in 2024, then skyrocketed by 34.14% to -$808502.0 in 2025.
  • Its EBT was -$808502.0 in Q3 2025, compared to -$1.4 million in Q2 2025 and -$851764.0 in Q1 2025.